A Study of Fluorescein Sodium in People Undergoing Vulvectomy for Extramammary Paget's Disease (EMPD)
This phase IV trial studies whether fluorescein sodium can be used to help surgeons identify tissue with cancer cells (cancerous tissue) that should be removed during surgery to remove part or all of the vulva (vulvectomy) for extramammary Paget disease (EMPD). Typically, when patients undergo vulvectomy for EMPD, surgeons use standard light to identify cancerous tissue that should be removed. One challenge with this approach is that the disease can display irregular spread within the skin that cannot always be detected by the naked eye. Fluorescein sodium is a contrast dye given as an intravenous (IV) infusion into the vein. The dye lights up under ultraviolet light. Research has shown that fluorescein sodium builds up in areas where there is cancer. This may help surgeons identify cancerous tissue that should be removed during vulvectomy for EMPD.